Polymer Conjugate As the New Promising Drug Delivery System for Combination Therapy Against Cancer

Overview

Journal Curr Top Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Jul 15

PMID 39005059

Authors

Qiang Hu

Yuannian Zhang

Jean Felix Mukerabigwi

Haili Wang

Yu Cao

Affiliations

Soon will be listed here.

Abstract

This review highlights the advantages of combination therapy using polymer conjugates as drug delivery systems for cancer treatment. In this review, the specific structures and materials of polymer conjugates, as well as the different types of combination chemotherapy strategies, are discussed. Specific targeting strategies, such as monoclonal antibody therapy and small molecule ligands, are also explored. Additionally, self-assembled polymer micelles and overcoming multidrug resistance are described as potential strategies for combination therapy. The assessment of combinational therapeutic efficacy and the challenges associated with polymer conjugates are also addressed. The future outlook aims to overcome these challenges and improve the effectiveness of drug delivery systems for combination therapy. The conclusion emphasizes the potential of polymer conjugates in combination therapy while acknowledging the need for further research and development in this field.

Citing Articles

Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy.

Parashar A, Saraogi G, Jain P, Kurmi B, Shrivastava V, Arora V Discov Oncol. 2024; 15(1):641.

PMID: 39527173 PMC: 11554983. DOI: 10.1007/s12672-024-01509-9.

References

Paskeh M, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi M . Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022; 15(1):83. PMC: 9238168. DOI: 10.1186/s13045-022-01305-4. View

Crosby D, Bhatia S, Brindle K, Coussens L, Dive C, Emberton M . Early detection of cancer. Science. 2022; 375(6586):eaay9040. DOI: 10.1126/science.aay9040. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Zajda J, Wroblewska A, Ruzik L, Matczuk M . Methodology for characterization of platinum-based drug's targeted delivery nanosystems. J Control Release. 2021; 335:178-190. DOI: 10.1016/j.jconrel.2021.05.022. View

Catalano A, Iacopetta D, Ceramella J, Scumaci D, Giuzio F, Saturnino C . Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies. Molecules. 2022; 27(3). PMC: 8839222. DOI: 10.3390/molecules27030616. View

Emran T, Shahriar A, Mahmud A, Rahman T, Abir M, Siddiquee M . Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front Oncol. 2022; 12:891652. PMC: 9262248. DOI: 10.3389/fonc.2022.891652. View

Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O . Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021; 39(6):845-865.e7. DOI: 10.1016/j.ccell.2021.04.014. View

Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A . Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022; 72(4):372-401. DOI: 10.3322/caac.21728. View

Plana D, Palmer A, Sorger P . Independent Drug Action in Combination Therapy: Implications for Precision Oncology. Cancer Discov. 2022; 12(3):606-624. PMC: 8904281. DOI: 10.1158/2159-8290.CD-21-0212. View

10.

Alamzadeh Z, Beik J, Pirhajati Mahabadi V, Abbasian Ardekani A, Ghader A, Kamrava S . Ultrastructural and optical characteristics of cancer cells treated by a nanotechnology based chemo-photothermal therapy method. J Photochem Photobiol B. 2019; 192:19-25. DOI: 10.1016/j.jphotobiol.2019.01.005. View

11.

Taguchi K, Okamoto Y, Matsumoto K, Otagiri M, Chuang V . When Albumin Meets Liposomes: A Feasible Drug Carrier for Biomedical Applications. Pharmaceuticals (Basel). 2021; 14(4). PMC: 8065628. DOI: 10.3390/ph14040296. View

12.

Mehta S, He T, Bajpayee A . Recent advances in targeted drug delivery for treatment of osteoarthritis. Curr Opin Rheumatol. 2020; 33(1):94-109. PMC: 8101446. DOI: 10.1097/BOR.0000000000000761. View

13.

Lombardo R, Musumeci T, Carbone C, Pignatello R . Nanotechnologies for intranasal drug delivery: an update of literature. Pharm Dev Technol. 2021; 26(8):824-845. DOI: 10.1080/10837450.2021.1950186. View

14.

van der Koog L, Gandek T, Nagelkerke A . Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization. Adv Healthc Mater. 2021; 11(5):e2100639. PMC: 11468589. DOI: 10.1002/adhm.202100639. View

15.

Iranpour S, Bahrami A, Nekooei S, Saljooghi A, Matin M . Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy. J Nanobiotechnology. 2021; 19(1):314. PMC: 8507230. DOI: 10.1186/s12951-021-01056-3. View

16.

Duncan R . The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003; 2(5):347-60. DOI: 10.1038/nrd1088. View

17.

Vasey P, Kaye S, Morrison R, Twelves C, Wilson P, Duncan R . Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999; 5(1):83-94. View

18.

Duncan R, Coatsworth J, Burtles S . Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum Exp Toxicol. 1998; 17(2):93-104. DOI: 10.1177/096032719801700204. View

19.

Singer J, Baker B, de Vries P, Kumar A, Shaffer S, Vawter E . Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol. 2003; 519:81-99. DOI: 10.1007/0-306-47932-X_6. View

20.

Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M . Drug release study of the chitosan-based nanoparticles. Heliyon. 2022; 8(1):e08674. PMC: 8741465. DOI: 10.1016/j.heliyon.2021.e08674. View